Scienture Holdings Inc. saw its stock rise by 18.13% in pre-market trading as it crossed above the 5-day SMA.
The company has signed an exclusive commercialization agreement with Summit Biosciences for the U.S. rights to Rezenopy (naloxone HCl) Nasal Spray, which is set to enhance its market position significantly. Summit will handle manufacturing and supply, while Scienture will manage sales and marketing, leveraging the product's patent protection effective January 2026. This agreement positions Scienture to capitalize on the growing naloxone market, which has annual sales of approximately $154 million.
This partnership not only strengthens Scienture's product portfolio but also reflects its commitment to addressing the opioid crisis, potentially leading to substantial revenue growth in the coming years.
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
